Dear Inigo

As Charles mentioned there are many many receptors studied and being studied. Your question in interesting in that you have asked which are the sensitive ones.

Oncologists and Researchers seem to have forgotten Youden's index which is a measure of the usefulness or uselessness of a diagnostic test, which receptor assay essentially is. It is a very simple statistic:

J=Sensitivity+specifcity-1. The value ranges from 0 to 1, 0 indicating a 'useless' test and 1 indicating useful one.

It is easy to calculate.

It would be nice if someone does this for all available receptor assays; it should be a boon for Research

Narayanan

Dear Inigo,

1- Gefi tinib is a selective inhibitor of the epidermal

growth factor (EGFR) tyrosine kinase, which is overexpressed

in many cancers, including non – small-cell lung cancer

(NSCLC). Attached is a recent paper on this receptor.

Hoping this will be helpful,

Rafik

Many cancer cell receptors are being studied, and it is complex to pinpoint what would make them 'sensitive': Prevalence of targeted cancer type, success in the clinic, amounts invested by companies, etc.

You can look up approved antibodies for cancer treatment to have a better idea or their variety.

You may consider narrowing your question to a type of cancer, drug carrier, or therapy in order to yield a short list of the most sensitive ones in that related area.

Hope this helps!

Dear Inigo

As Charles mentioned there are many many receptors studied and being studied. Your question in interesting in that you have asked which are the sensitive ones.

Oncologists and Researchers seem to have forgotten Youden's index which is a measure of the usefulness or uselessness of a diagnostic test, which receptor assay essentially is. It is a very simple statistic:

J=Sensitivity+specifcity-1. The value ranges from 0 to 1, 0 indicating a 'useless' test and 1 indicating useful one.

It is easy to calculate.

It would be nice if someone does this for all available receptor assays; it should be a boon for Research

Narayanan

TLR3 is currently studied, particularly in terms of diagnosis and especially for its relatively inexpensive ligand but extremely effective: Poly I; C

Two products are in clinical trial: a PEGylated form and polylysine form.

ONCOVIR Hiltonol R is the product giving promising results so far.

However these results are limited because the diagnosis TLR3 + is not taken into concideration, and is not associated with patient selection.

Further studies are being conducted to induce TLR3 on tumor cell and making the cell susceptible to treatment with ligand.

Thank you all so much for the responses!. Really appreciate it!. Will look into all this. Certainly this area is of great interest and future in cancer research. 

Dear Millan. To add up on all the best answers you got, its better you divide receptor expression in cancer cells into 2 broad categories. General receptors which are expressed in virtually all cancer cells then Special receptors expressed solely on the cancer of that organ . then you can also focus yourself on organ specific cancer stem cell markers

Thank you very much Dr. Arshad. At this point I am more interested in general cancer cell receptors that are not present in normal cells. thanks!

TLRs and NLRs are also interesting in cancer

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514171/